Stock Market News

H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating

wcc wcc
Mar 06, 2026 - 15:50
0 0
H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating
Previous Article

RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to ...

Next Article

Petrobras 2025 net income jumps 160% to $19.6bn

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Wow Wow 0
Sad Sad 0
Angry Angry 0
wcc
wcc

Related Posts

Commerzbank Says Some Institutional Investors Have Accepted UniCredit’s Offer

Commerzbank Says Some Institutional Investors Have A...

wcc
Jun 26, 2026
0
0
WhatsApp's pick of Indian fintech founder signals scale of payment ambitions

WhatsApp's pick of Indian fintech founder signals sc...

wcc
Jun 26, 2026
0
0
Ask an Advisor: I'm 43 With $315K in an IRA, $90K in a Roth and Maxed-Out 401(k) Contributions. Can I Afford to Retire at 57?

Ask an Advisor: I'm 43 With $315K in an IRA, $90K in...

wcc
Jun 26, 2026
0
0
H&M Earnings Hit by One-Off Costs as Turnaround Efforts Continue

H&M Earnings Hit by One-Off Costs as Turnaround Effo...

wcc
Jun 26, 2026
0
0
Market Update: BDX, DD

Market Update: BDX, DD

wcc
Jun 26, 2026
0
0
Meet the Spectacular ETF With 32.8% of Its Portfolio Parked in Nvidia, Apple, Broadcom, and Alphabet

Meet the Spectacular ETF With 32.8% of Its Portfolio...

wcc
Jun 26, 2026
0
0

Comments (0)

User